UK Markets close in 1 hr

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.8000-0.2300 (-5.71%)
As of 04:00PM EST. Market open.

Achilles Therapeutics plc

245 Hammersmith Road
London W6 8PW
United Kingdom
44 20 8154 4600
https://www.achillestx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees153

Key executives

NameTitlePayExercisedYear born
Dr. Iraj AliCEO & DirectorN/AN/A1976
Dr. Karl Peggs M.D.Founder & Chief Medical OfficerN/AN/A1967
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICRFounderN/AN/A1963
Dr. Charles SwantonFounderN/AN/A1972
Dr. Sergio A. Quezada Ph.D.Founder & Chief Scientific OfficerN/AN/A1975
Mr. Robert CouttsChief Financial OfficerN/AN/A1984
Mr. Lee M. SternVP of Investor Relations & External CommunicationsN/AN/AN/A
Mr. Daniel HoodChief Legal OfficerN/AN/AN/A
Julia WilsonHead of CommunicationsN/AN/AN/A
Mr. Tariq AhmedVP of PeopleN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Corporate governance

Achilles Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.